Cook Biotech Incorporated (CBI), located in the Purdue Research Park in West Lafayette, Indiana, was established in 1995 following a Purdue University biomedical engineering research teams' discovery of the unique properties of porcine small intestine submucosa. Since the company was founded, CBI has developed and currently manufactures advanced tissue repair products for worldwide distribution.
Cook Biotech's products are based on extracellular matrix (ECM) technology. The source for the ECM is derived from porcine small intestine and is known to have unique tissue remodeling benefits.
Using a variety of surgical procedures, the grafts are placed to repair or reinforce damaged tissue. Once in place, the graft provides a scaffold-like structure and communicates with the body, signaling surrounding tissue to grow across the scaffold. This action supports the healing process by attracting cells and nutrients to the area. Over time, the graft is remodeled into fully vascularized tissue and becomes as strong as the patient's own tissue.
The products are used in hernia repair, fistula repair, plastic surgery, staple line reinforcement, continence restoration, Peyronie's disease, dural repair and pelvic floor repair. A sister product, OASIS® Wound Matrix, is used to treat disease-induced skin ulcers, burns and pressure sores.
Together with a network of research scientists and medical practitioners, CBI is identifying the medical needs most compatible with ECM technology and is developing products to meet those needs.
